Genmab A/S (NASDAQ:GMAB) shares traded -6.73% lower at $40.31 on Wall Street last session.
In accordance with the data, 27 analysts cover Genmab A/S (NASDAQ:GMAB). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $53.00 and a low of $30.10, we find $44.07. Given the previous closing price of $43.22, this indicates a potential upside of 1.97 percent. GMAB stock price is now -6.64% away from the 50-day moving average and 10.62% away from the 200-day moving average. The market capitalization of the company currently stands at $26.27B.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
It has been rated a hold by 12 analysts and a buy by 9. Brokers who have rated the stock have averaged $43.69 as their price target over the next twelve months.
, while ‘Deutsche Bank’ rates the stock as ‘Hold’.
There have been several recent changes in the stakes of large investors in GMAB stock. A new stake in Genmab A/S shares was purchased by ALLIANCEBERNSTEIN L.P. during the first quarter worth $232,971,000. FIRST TRUST ADVISORS LP invested $52,060,000 in shares of GMAB during the first quarter. In the first quarter, CAAS CAPITAL MANAGEMENT LP acquired a new stake in Genmab A/S valued at approximately $14,109,000. MILLENNIUM MANAGEMENT LLC acquired a new stake in GMAB for approximately $4,903,000. HUDSON BAY CAPITAL MANAGEMENT LP purchased a new stake in GMAB valued at around $3,095,000 in the second quarter. In total, there are 232 active investors with 6.90% ownership of the company’s stock.
Genmab A/S (NASDAQ: GMAB) opened at $41.29 on Wednesday. During the past 12 months, Genmab A/S has had a low of $26.19 and a high of $47.50. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 9.60, and a quick ratio of 9.60. The fifty day moving average price for GMAB is $43.18 and a two-hundred day moving average price translates $36.44 for the stock.
The latest earnings results from Genmab A/S (NASDAQ: GMAB) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at $0.41, missing analysts’ expectations of $1.55 by -1.14. This compares to $0.21 EPS in the same period last year. The net profit margin was 47.20% and return on equity was 23.50% for GMAB. The company reported revenue of $552.97 million for the quarter, compared to $366.37 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 50.93 percent. For the current quarter, analysts expect GMAB to generate $464.26M in revenue.
Genmab A/S(GMAB) Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company’s also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
